Clorox (CLX) Given a $138.00 Price Target by Barclays Analysts

Barclays set a $138.00 price target on Clorox (NYSE:CLX) in a research report report published on Thursday. The firm currently has a hold rating on the stock.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Clorox from a hold rating to a buy rating and set a $171.00 price objective for the company in a report on Wednesday, October 3rd. Argus raised shares of Clorox from a hold rating to a buy rating and set a $175.00 price objective for the company in a report on Tuesday, September 25th. ValuEngine raised shares of Clorox from a hold rating to a buy rating in a report on Saturday, September 22nd. BMO Capital Markets reaffirmed a buy rating and set a $153.00 price objective on shares of Clorox in a report on Friday, August 3rd. Finally, Wells Fargo & Co reaffirmed a hold rating on shares of Clorox in a report on Wednesday. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Clorox has an average rating of Hold and an average price target of $139.71.

NYSE CLX traded up $0.08 on Thursday, reaching $153.81. 800,100 shares of the stock were exchanged, compared to its average volume of 1,100,293. Clorox has a one year low of $113.57 and a one year high of $155.23. The stock has a market cap of $19.51 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 3.65 and a beta of 0.36. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 3.15.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.59 by $0.03. Clorox had a net margin of 13.44% and a return on equity of 103.18%. The business had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same period last year, the firm posted $1.46 EPS. The company’s revenue was up 4.2% on a year-over-year basis. Sell-side analysts forecast that Clorox will post 6.41 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 16th. Investors of record on Wednesday, October 31st will be issued a $0.96 dividend. This represents a $3.84 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend is Tuesday, October 30th. Clorox’s dividend payout ratio (DPR) is presently 61.34%.

In other Clorox news, EVP Laura Stein sold 12,880 shares of Clorox stock in a transaction on Friday, August 31st. The shares were sold at an average price of $144.10, for a total transaction of $1,856,008.00. Following the completion of the transaction, the executive vice president now directly owns 74,483 shares of the company’s stock, valued at $10,733,000.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Linda J. Rendle sold 382 shares of Clorox stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $148.32, for a total transaction of $56,658.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,268 shares of company stock valued at $4,196,686. 1.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Parnassus Investments CA boosted its stake in Clorox by 1.6% during the second quarter. Parnassus Investments CA now owns 4,711,970 shares of the company’s stock worth $637,294,000 after buying an additional 76,149 shares during the period. Macquarie Group Ltd. boosted its stake in Clorox by 437,400.0% during the second quarter. Macquarie Group Ltd. now owns 1,750,000 shares of the company’s stock worth $236,688,000 after buying an additional 1,749,600 shares during the period. Schroder Investment Management Group boosted its stake in Clorox by 57.0% during the second quarter. Schroder Investment Management Group now owns 1,506,358 shares of the company’s stock worth $201,641,000 after buying an additional 547,070 shares during the period. Morgan Stanley boosted its stake in Clorox by 44.2% during the second quarter. Morgan Stanley now owns 1,101,380 shares of the company’s stock worth $148,962,000 after buying an additional 337,621 shares during the period. Finally, Swiss National Bank boosted its stake in Clorox by 1.9% during the second quarter. Swiss National Bank now owns 955,992 shares of the company’s stock worth $129,298,000 after buying an additional 17,600 shares during the period. 78.38% of the stock is owned by institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

See Also: Google Finance

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply